Phase I study of KRN330 monoclonal antibody in patients with colorectal cancer

Trial Profile

Phase I study of KRN330 monoclonal antibody in patients with colorectal cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs KRN 330 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 26 Feb 2009 New source identified and integrated (Vanderbilt-Ingram Cancer Center registry record).
    • 05 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top